Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment

Bray, Victoria; Dhillon, Haryana M.; Vardy, Janette L.

doi:10.1007/s11764-018-0692-x

Cited by 131 publications

(151 citation statements)

References 119 publications

Supporting

Mentioning

133

Contrasting

Unclassified

Order By: Relevance

“…This was the first review to summarize findings from longitudinal studies on SCI. During data synthesis, a review of SCI (including longitudinal data) was published. As the main purposes of the previous review (ie, the association with SCI) is different, our synthesis provides a unique contribution to the literature.…”

Section: Discussionmentioning

confidence: 99%

Systematic review of longitudinal studies on chemotherapy‐associated subjective cognitive impairment in cancer patients

et al. 2020

View full text Add to dashboard Cite

Objectives: This systematic review of longitudinal studies, assessing subjective cognitive impairment (SCI) reported by adult cancer patients, aimed to summarize evidence on the impact of chemotherapy on SCI, identify moderators of SCI, and evaluate methodological issues. Methods: Data accrued from Pubmed, EMBASE, CINAHL, PsychInfo, and the Cochrane library. Inclusion criteria were original studies, an exclusively adult sample, valid and reliable subjective cognitive measures, and at least one baseline data point prior to and another after the initiation of chemotherapy. Data were collected on the sample composition, data-collection time points, outcome measures, statistical analysis, and major findings (ie, longitudinal changes in prevalence, severity, and associated factors).Results: Forty articles published between 2004 and 2019 were retained: 21 examined chemotherapy-treated patients only, and 19 employed control groups. Findings were mixed, with slightly more studies supporting the impact of chemotherapy on SCI. SCI tended to be more prevalent and severe after initiating chemotherapy, compared with patients' own baseline and controls not treated with chemotherapy. Impact appeared to be acute and more likely limited to subsamples. Most studies examining non-breast-cancer samples reported the lack or limited impact of chemotherapy on SCI. The most consistent moderators were depression and fatigue. Methodological issues regarding sampling design, measurement, and statistical analysis were discussed.Conclusion: More rigorously designed longitudinal studies would clarify direct and indirect effects of chemotherapy on SCI. K E Y W O R D S anxiety, cancer, cognitive function, cognitive impairment, depression, fatigue, oncology, systematic review

show abstract

Section: Discussionmentioning

confidence: 99%

Systematic review of longitudinal studies on chemotherapy‐associated subjective cognitive impairment in cancer patients

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Cognitive complaints were reported by ≥50% of breast cancer patients after chemotherapy; however, only 15-25% had objective cognitive decline [57]. Cognitive complaints, often reported by patients with poor emotional status or reported fatigue, are not always linked to objective cognitive disorders [58]. Indeed, many studies showed an association between reported cognitive complaints and psychological factors such as depression [59][60][61] or anxiety [61,62], as well as with fatigue and sleep difficulties [63,64].…”

Section: Long-term Cognitive Disorders In Breast Cancer Survivorsmentioning

confidence: 99%

Long-Term Fatigue and Cognitive Disorders in Breast Cancer Survivors

Joly

Lange

Santos

et al. 2019

Cancers

View full text Add to dashboard Cite

Survivors of early-stage breast cancer may report treatment-related side effects that persist for several years after the end of primary treatment. Among these, fatigue and cognitive disorders are frequent complaints and can negatively impact quality of life. Cancer-related fatigue is a very prevalent and distressing long-term side effect among breast cancer survivors that typically improves after completion of treatment, although many patients report severe fatigue several years post-treatment. Cognitive disorders are also common among survivors of breast cancer, especially if treated with chemotherapy. These symptoms are usually mild-to-moderate and often transient. Cognitive recovery is frequently observed within months or a few years after completion of chemotherapy or endocrine therapy. However, some breast cancer survivors may have persistent cognitive difficulties. Several types of interventions have proved to be beneficial in reducing cancer-related fatigue and cognitive difficulties. Most of these interventions for cancer-related fatigue are thought to be effective by reducing inflammation or disrupting pro-inflammatory circuits. Further studies are needed on cognitive management that has showed promising results. This narrative review summarizes the state of the art regarding long-term fatigue and cognitive disorders in patients with early breast cancer, describing prevalence, impact, pathophysiology, and risk factors, and focusing on available interventions.

show abstract

“…Due to the significant impact on the patient's quality of life (Boykoff, Moieni, & Subramanian, ; Hutchinson, Hosking, & Kichenadasse, ; Lange & Joly, ), a growing body of neuropsychological and neuroimaging studies focuses on cognitive impairment in cancer patients (Joly et al, ). Nevertheless, considering the frequent discrepancies between subjective reports of cognitive difficulties and objective measures from neuropsychological tests (Bray, Dhillon, & Vardy, ; Hutchinson et al, ; Pullens, De Vries, & Roukema, ), overall cancer patients' cognitive complaints do not seem to be good predictors of their objective performances.…”

Section: Introductionmentioning

confidence: 99%

The role of metamemory on cognitive complaints in cancer patients

et al. 2020

View full text Add to dashboard Cite

Objective: Although cancer patients frequently report cognitive disturbances, it is commonly asserted a lack of association between cognitive complaints and neuropsychological test performances. Our goal was to better understand the relationships between subjective and objective cognitive scores through a metamemory monitoring assessment.Methods: Sixty cancer patients currently treated by chemotherapy and/or targeted therapy, and 30 healthy controls (HC) were included. Cognitive complaint was assessed by FACT-cog, QAM and DEX questionnaires. One or more z-scores ≤−1.65 among these three questionnaires defined the presence of cognitive complaints.Objective cognitive performances assessed episodic memory, processing speed and executive functions/working memory (ESR paradigm, TMT, Stroop, n-back).Metamemory was assessed with a Judgment of Learning (JOL) task. Results:Patients with cognitive complaints had significantly more depressive and anxiety symptoms (ps < .004), and lower performances on several cognitive tests (ps < .05) than both patients without complaints and HC. More specifically, analy-

show abstract

Systematic review of self-reported cognitive function in cancer patients following chemotherapy treatment

Abstract: This research highlights the need for a standardised approach to measurement of self-reported cognitive symptoms in cancer patients.

Cited by 131 publications

References 119 publications

Systematic review of longitudinal studies on chemotherapy‐associated subjective cognitive impairment in cancer patients

Systematic review of longitudinal studies on chemotherapy‐associated subjective cognitive impairment in cancer patients

Long-Term Fatigue and Cognitive Disorders in Breast Cancer Survivors

The role of metamemory on cognitive complaints in cancer patients

Contact Info

Product

Resources

About